Ivana Jeziskova

Ivana Jeziskova

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2010 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
DDDana Dvorakova
Dana Dvorakova
ZRZdenek Racil
Zdenek Racil
IJIvana Jeziskova
Ivana Jeziskova
IPIvo Palasek
Ivo Palasek
MPMarketa Protivankova
Marketa Protivankova
JMJiri Mayer
Jiri Mayer
Nucleophosmin (NPM1) mutations in exon 12 are the most common genetic alternation in cytogenetically normal AML (CN‐AML). Although mutation types A, B, and D represent the majority of cases, rare mutation variants of the NPM1 gene in individual patients do occur. In this study, we have evaluated a novel, DNA‐based real‐time quantitative polymerase chain reaction (RQ‐PCR) for the detection of three of the most commonly occurring mutations and for six rare patient‐specific mutation types, which represent 28% of all of the NPM1 mutations in our group of 25 CN‐AML patients. Furthermore, the prognostic relevance of NPM1‐based monitoring of minimal residual disease (MRD) in peripheral blood (PB), bone marrow (BM), and in specific cell subsets (CD34+, CD34−, CD34dim) of BM were evaluated. In 80% of the evaluable patients, a molecular relapse preceded a hematological relapse. Moreover, in this subset of patients, the molecular relapse occurred at a median of 97 days before the hematological relapse. Our compartment analysis showed a strong correlation between BM and PB (r = 0.907, P < 0.001) as well as a high copy number of mutated NPM1 in CD34+ BM cells. In conclusion, we have demonstrated applicability of our presented RQ‐PCR method for a large percentage of mutated NPM1 patients with CN‐AML as well as the usefulness for long‐term follow‐up monitoring of MRD and the prediction of hematological relapse. Am. J. Hematol., 2010.

1 June 2009 in Experimental Hematology
Verified
Journal Article
Closed access
MDMichael Doubek
Michael Doubek
IPIvo Palasek
Ivo Palasek
ZPZdenek Pospisil
Zdenek Pospisil
MBMarek Borsky
Marek Borsky
MKMartin Klabusay
Martin Klabusay
JMJiri Mayer
Jiri Mayer

10 January 2011 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
OHO. Horky
O. Horky
JMJ. Mayer
J. Mayer
LKL. Kablaskova
L. Kablaskova
FRF. Razga
F. Razga
MKM. Krejci
M. Krejci
DDD. Dvorakova
D. Dvorakova

17 May 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
MPMaria Agustina Perusini
Maria Agustina Perusini
DŽDaniela Žáčková
Daniela Žáčková
TKTaehyung Kim
Taehyung Kim
KPKatia Pagnano
Katia Pagnano
CPCarolina Pavlovsky
Carolina Pavlovsky
DKDennis Dong Hwan Kim
Dennis Dong Hwan Kim
Advancements in genomics are transforming the clinical management of chronic myeloid leukemia (CML) toward precision medicine. The impact of somatic mutations on treatment outcomes is still under debate. We studied the association of somatic mutations in epigenetic modifier genes and activated signaling/myeloid transcription factors (AS/MTFs) with disease progression and treatment failure in patients with CML after tyrosine kinase inhibitor (TKI) therapy. A total of 394 CML samples were sequenced, including 254 samples collected at initial diagnosis and 140 samples taken during follow-up. Single-molecule molecular inversion probe (smMIP)–based next-generation sequencing (NGS) was conducted targeting recurrently mutated loci in 40 genes, with a limit of detection of 0.2%. Seventy mutations were detected in 57 diagnostic samples (22.4%), whereas 64 mutations were detected in 39 of the follow-up samples (27.9%). Carrying any mutation at initial diagnosis was associated with worse outcomes after TKI therapy, particularly in AS/MTF genes. Patients having these mutations at initial diagnosis and treated with imatinib showed higher risks of treatment failure (hazard ratio, 2.53; 95% confidence interval, 1.13-5.66; P = .0239). The adverse prognostic impact of the mutations was not clear for patients treated with second-generation TKIs. The multivariate analysis affirmed that mutations in AS/MTF genes independently serve as adverse prognostic factors for molecular response, failure-free survival, and progression risk. Additionally, there was an observable nonsignificant trend indicating a heightened risk of progression to advanced disease and worse overall survival. In conclusion, mutations in the AS/MTF genes using smMIP-based NGS can help identify patients with a potential risk of both treatment failure and progression and may help upfront TKI selection.

20 August 2015 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
IJIvana Jeziskova
Ivana Jeziskova
MMMilena Musilova
Milena Musilova
MCMartin Culen
Martin Culen
VFVeronika Foltankova
Veronika Foltankova
DDDana Dvorakova
Dana Dvorakova
ZRZdenek Racil
Zdenek Racil

28 September 2012 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
IJIvana Jeziskova
Ivana Jeziskova
FRFilip Razga
Filip Razga
MTMartina Toskova
Martina Toskova
DDDana Dvorakova
Dana Dvorakova
STShira Timilsina
Shira Timilsina
ZRZdenek Racil
Zdenek Racil